Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.

@article{Arnold2010EmpiricTF,
  title={Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.},
  author={Amy Maria Arnold and Sara D. Brouse and W. Douglas Pitcher and Ronald G Hall},
  journal={Journal of intensive care medicine},
  year={2010},
  volume={25 5},
  pages={
          259-70
        }
}
Nosocomial pneumonia is a major cause of morbidity and mortality for hospitalized patients. Antimicrobial resistance is increasing, creating a strain between ensuring the provision of adequate empiric therapy and slowing the development of antimicrobial resistance. Excessive antimicrobial therapy places patients are at greater risk of drug interactions, adverse events, and superinfections. Ways to maximize adequate empiric therapy include (1) categorizing each patient's risk of being infected… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Rationale and evidence for extended infusion of piperacillin-tazobactam.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 94 REFERENCES

Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.

  • International journal of clinical pharmacology and therapeutics
  • 2005
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Cefepime (marketed as Maxipime)

Information for Healthcare Professionals
  • June 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm167254.htm
  • 2009
VIEW 1 EXCERPT

Similar Papers